KRMD vs. BWAY, ALUR, BLUA, TELA, STIM, NVNO, SEPA, MGRM, SRTS, and PDEX
Should you be buying KORU Medical Systems stock or one of its competitors? The main competitors of KORU Medical Systems include BrainsWay (BWAY), Allurion Technologies (ALUR), BlueRiver Acquisition (BLUA), TELA Bio (TELA), Neuronetics (STIM), enVVeno Medical (NVNO), SEP Acquisition (SEPA), Monogram Orthopaedics (MGRM), Sensus Healthcare (SRTS), and Pro-Dex (PDEX). These companies are all part of the "surgical & medical instruments" industry.
BrainsWay (NASDAQ:BWAY) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk.
BrainsWay has a net margin of -4.83% compared to BrainsWay's net margin of -45.24%. KORU Medical Systems' return on equity of -3.98% beat BrainsWay's return on equity.
BrainsWay received 26 more outperform votes than KORU Medical Systems when rated by MarketBeat users. Likewise, 64.58% of users gave BrainsWay an outperform vote while only 60.00% of users gave KORU Medical Systems an outperform vote.
30.1% of BrainsWay shares are held by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are held by institutional investors. 19.0% of BrainsWay shares are held by insiders. Comparatively, 25.6% of KORU Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
BrainsWay has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
BrainsWay currently has a consensus price target of $9.67, indicating a potential upside of 79.01%. KORU Medical Systems has a consensus price target of $3.50, indicating a potential upside of 48.31%. Given KORU Medical Systems' higher probable upside, equities research analysts clearly believe BrainsWay is more favorable than KORU Medical Systems.
BrainsWay has higher revenue and earnings than KORU Medical Systems. BrainsWay is trading at a lower price-to-earnings ratio than KORU Medical Systems, indicating that it is currently the more affordable of the two stocks.
In the previous week, BrainsWay had 11 more articles in the media than KORU Medical Systems. MarketBeat recorded 14 mentions for BrainsWay and 3 mentions for KORU Medical Systems. BrainsWay's average media sentiment score of 0.94 beat KORU Medical Systems' score of 0.89 indicating that KORU Medical Systems is being referred to more favorably in the news media.
Summary
BrainsWay beats KORU Medical Systems on 11 of the 18 factors compared between the two stocks.
Get KORU Medical Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KORU Medical Systems Competitors List
Related Companies and Tools
